Ascendiant Capital Markets Lowers PAVmed (NASDAQ:PAVM) Price Target to $21.00

PAVmed (NASDAQ:PAVM) had its price target decreased by analysts at Ascendiant Capital Markets from $22.00 to $21.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Lake Street Capital raised shares of PAVmed to a “strong-buy” rating in a research report on Wednesday, May 15th.

PAVmed Stock Up 9.2 %

Shares of NASDAQ:PAVM opened at $1.19 on Tuesday. PAVmed has a twelve month low of $0.60 and a twelve month high of $9.00. The stock’s 50 day moving average is $0.88 and its 200-day moving average is $1.50. The firm has a market capitalization of $12.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.66.

PAVmed (NASDAQ:PAVM) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.84) earnings per share for the quarter. The business had revenue of $0.98 million for the quarter. Equities research analysts anticipate that PAVmed will post -5.88 earnings per share for the current fiscal year.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.